Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions

• Published in: Netherlands heart journal Vol. 20; no. 11; pp. 439 - 446
• Main Authors: Grundeken, M. J., Smits, M., Harskamp, R. E., Damman, P., Woudstra, P., Hoorweg, A. J., Baan, J., Arkenbout, E. K., Piek, J. J., Vis, M. M., Henriques, J. P. S., Koch, K. T., Tijssen, J. G., de Winter, R. J., Wykrzykowska, J. J.
• Format: Journal Article
• Language: English
• Published: Heidelberg Bohn Stafleu van Loghum 01.11.2012
• Subjects: Cardiology; Medical Education; Medicine; Medicine & Public Health; Original; Original Article; Percutaneous coronary intervention; Dedicated bifurcation device; Coronary artery disease; Bifurcation lesions
• ISSN: 1568-5888; 1876-6250
• DOI: 10.1007/s12471-012-0302-x

Aims Percutaneous coronary intervention (PCI) of a bifurcation lesion (BL) is still associated with poorer clinical outcomes when compared with PCI of a non-BL. Therefore, several dedicated coronary bifurcation stents, such as the Tryton Side Branch Stent™ (Tryton Medical, Durham, NC, USA), were developed to improve clinical outcomes. We investigated 6-month clinical outcomes after placement of a Tryton stent in 91 patients treated for 93 BLs in our centre. Methods and results All consecutive patients who have undergone PCI of a BL treated with the Tryton stent in our centre were included. Outcomes were defined as any death, cardiac death, myocardial infarction (MI), any revascularisation, ischaemia-driven target vessel revascularisation (TVR), ischaemia-driven target lesion revascularisation (TLR), stent thrombosis, and target vessel failure (TVF; composite of cardiac death, MI, and ischaemia-driven TVR). Event rates were estimated using the Kaplan-Meier method. Thirty-eight (42 %) patients with acute coronary syndrome (ACS) were included (16 % ST-segment elevation MI (STEMI)). The 6-month event rates were 5.4 % (death), 4.3 % (cardiac death), 2.2 % (MI), 4.5 % (any revascularisation), 4.5 % (TVR), 4.5 % (TLR) and 9.7 % (TVF). Conclusion In a real-world all-comers single-centre registry, the use of the Tryton Side Branch Stent was associated with acceptable procedural and promising clinical outcomes at 6 months, including ACS and STEMI patients.